In a year of mixed fortunes for ATR, the turboprop manufacturer netted 50 orders in 2025 but fell short of its production target, delivering 32 aircraft, three fewer than 2024.
AstraZeneca has had a setback in its late-stage oncology pipeline, after AKT inhibitor ceralasertib, given in combination with cancer immunotherapy Imfinzi, failed to extend survival in a lung cancer ...
Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your inbox, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results